Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus chemotherapy as second-line treatment in advanced solid tumors
ChiCTR-OPN-16009458Phase 4Recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jan 1990
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in bronchial carcinoma, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 1 more, sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: Progression-Free Survival, Disease control rate and 1 more. Started Jan 1990; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
bronchial carcinomagastric cancer (GC)gastroesophageal junction adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-OPN-16009458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-16009458.